Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/12/2018 | 11:03pm CEST

By Bowdeya Tweh

Johnson & Johnson (JNJ) has accepted private-equity firm Platinum Equity's offer to buy its LifeScan business for about $2.1 billion, as the pharmaceuticals and medical-device maker moves forward with plans to streamline its business.

J&J said Tuesday that the deal for LifeScan, which makes blood-glucose monitoring equipment, is expected to close by the end of the year. More than 20 million people world-wide use LifeScan's OneTouch brand products to help them manage diabetes, J&J said.

The New Brunswick, N.J., company said it received Platinum Equity's offer in March.

Shares in J&J fell 0.4% in after-hours trading.

Write to Bowdeya Tweh at bowdeya.tweh@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.58% 136.5301 Delayed Quote.-3.76%
PLATINUM 0.82% 793.86 Delayed Quote.-15.54%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:55pJOHNSON & JOHNSON : Janssen Reports Positive Topline Results for ATLAS Phase III..
AQ
04:36pJOHNSON & JOHNSON : World Health Organization recommends the use of bedaquiline ..
PU
04:31pJOHNSON & JOHNSON : to Host Investor Conference Call on the Pharmaceutical Busin..
PU
04:20pJOHNSON & JOHNSON : to Host Investor Conference Call on the Pharmaceutical Busin..
PR
04:11pJOHNSON & JOHNSON : Makes Fortune's 2018 Change the World List
PU
08/17ANALYSIS OF THE GLOBAL CARDIAC RESYN : Some of the prominent participants in the..
AQ
08/17Pfizer joins DOJ probe into claims pharma bribes funded Iraqi terrorists
AQ
08/16JOHNSON & JOHNSON : Announces Chris DelOrefice as Vice President of Investor Rel..
AQ
08/16JOHNSON & JOHNSON : Janssen Submits U.S. & EU Regulatory Applications Seeking Ap..
AQ
08/16MEDICAL EDUCATION MARKET TO GROW AT : Medical Education Market – Global I..
AQ
More news
News from SeekingAlpha
11:08aBig Pharma in the green in early trade 
11:00aJohnson & Johnson to update on pharma business September 13 
07:49aANTARES PHARMA : Proven Business Model Set To Move Much Higher 
08/18YOUR DAILY PHARMA SCOOP : Catalyst Positive, JNJ Succeeds, Blue Chips Support Ti.. 
08/18'Safer' Dividend Aristocrats Show 12.9%-28.2% Top Gains By 10 
Financials ($)
Sales 2018 81 206 M
EBIT 2018 24 972 M
Net income 2018 16 036 M
Debt 2018 11 222 M
Yield 2018 2,66%
P/E ratio 2018 19,85
P/E ratio 2019 17,17
EV / Sales 2018 4,58x
EV / Sales 2019 4,34x
Capitalization 361 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 6,4%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-3.76%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY22.73%183 667
AMGEN13.53%127 784